vs
Okta, Inc.（OKTA）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Okta, Inc.的1.0倍（$772.1M vs $742.0M），Revvity净利率更高（12.7% vs 5.8%，领先6.9%），Okta, Inc.同比增速更快（11.6% vs 5.9%），Okta, Inc.自由现金流更多（$214.0M vs $161.8M），过去两年Okta, Inc.的营收复合增速更高（10.7% vs 9.0%）
Okta是总部位于美国旧金山的身份与访问管理服务商，成立于2009年，主打云软件产品，可助力企业管理和保障用户应用访问认证安全，同时支持开发者在应用、网站、网络服务及设备中嵌入身份管控功能，2017年上市时估值超60亿美元。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
OKTA vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.0倍
$742.0M
营收增速更快
OKTA
高出5.7%
5.9%
净利率更高
RVTY
高出6.9%
5.8%
自由现金流更多
OKTA
多$52.2M
$161.8M
两年增速更快
OKTA
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $742.0M | $772.1M |
| 净利润 | $43.0M | $98.4M |
| 毛利率 | 77.1% | — |
| 营业利润率 | 3.1% | 14.5% |
| 净利率 | 5.8% | 12.7% |
| 营收同比 | 11.6% | 5.9% |
| 净利润同比 | 168.8% | 3.9% |
| 每股收益（稀释后） | $0.24 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OKTARVTY
| Q4 25 | $742.0M | $772.1M | ||
| Q3 25 | $728.0M | $698.9M | ||
| Q2 25 | $688.0M | $720.3M | ||
| Q1 25 | $682.0M | $664.8M | ||
| Q4 24 | $665.0M | $729.4M | ||
| Q3 24 | $646.0M | $684.0M | ||
| Q2 24 | $617.0M | $691.7M | ||
| Q1 24 | $605.0M | $649.9M |
净利润OKTARVTY
| Q4 25 | $43.0M | $98.4M | ||
| Q3 25 | $67.0M | $46.7M | ||
| Q2 25 | $62.0M | $53.9M | ||
| Q1 25 | $23.0M | $42.2M | ||
| Q4 24 | $16.0M | $94.6M | ||
| Q3 24 | $29.0M | $94.4M | ||
| Q2 24 | $-40.0M | $55.4M | ||
| Q1 24 | $-44.0M | $26.0M |
毛利率OKTARVTY
| Q4 25 | 77.1% | — | ||
| Q3 25 | 76.9% | 53.6% | ||
| Q2 25 | 77.5% | 54.5% | ||
| Q1 25 | 76.8% | 56.5% | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 76.0% | 56.3% | ||
| Q2 24 | 76.0% | 55.7% | ||
| Q1 24 | 76.0% | 54.6% |
营业利润率OKTARVTY
| Q4 25 | 3.1% | 14.5% | ||
| Q3 25 | 5.6% | 11.7% | ||
| Q2 25 | 5.7% | 12.6% | ||
| Q1 25 | 1.2% | 10.9% | ||
| Q4 24 | -2.4% | 16.3% | ||
| Q3 24 | -2.9% | 14.3% | ||
| Q2 24 | -7.6% | 12.4% | ||
| Q1 24 | -13.7% | 6.8% |
净利率OKTARVTY
| Q4 25 | 5.8% | 12.7% | ||
| Q3 25 | 9.2% | 6.7% | ||
| Q2 25 | 9.0% | 7.5% | ||
| Q1 25 | 3.4% | 6.4% | ||
| Q4 24 | 2.4% | 13.0% | ||
| Q3 24 | 4.5% | 13.8% | ||
| Q2 24 | -6.5% | 8.0% | ||
| Q1 24 | -7.3% | 4.0% |
每股收益（稀释后）OKTARVTY
| Q4 25 | $0.24 | $0.86 | ||
| Q3 25 | $0.37 | $0.40 | ||
| Q2 25 | $0.35 | $0.46 | ||
| Q1 25 | $0.15 | $0.35 | ||
| Q4 24 | $0.00 | $0.77 | ||
| Q3 24 | $0.15 | $0.77 | ||
| Q2 24 | $-0.24 | $0.45 | ||
| Q1 24 | $-0.26 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $6.9B | $7.3B |
| 总资产 | $9.2B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OKTARVTY
| Q4 25 | $2.5B | $919.9M | ||
| Q3 25 | $2.9B | $931.4M | ||
| Q2 25 | $2.7B | $991.8M | ||
| Q1 25 | $2.5B | $1.1B | ||
| Q4 24 | $2.2B | $1.2B | ||
| Q3 24 | $2.4B | $1.2B | ||
| Q2 24 | $2.3B | $2.0B | ||
| Q1 24 | $2.2B | $1.7B |
股东权益OKTARVTY
| Q4 25 | $6.9B | $7.3B | ||
| Q3 25 | $6.8B | $7.4B | ||
| Q2 25 | $6.6B | $7.6B | ||
| Q1 25 | $6.4B | $7.6B | ||
| Q4 24 | $6.3B | $7.7B | ||
| Q3 24 | $6.1B | $7.9B | ||
| Q2 24 | $6.0B | $7.9B | ||
| Q1 24 | $5.9B | $7.8B |
总资产OKTARVTY
| Q4 25 | $9.2B | $12.2B | ||
| Q3 25 | $9.6B | $12.1B | ||
| Q2 25 | $9.4B | $12.4B | ||
| Q1 25 | $9.4B | $12.4B | ||
| Q4 24 | $9.0B | $12.4B | ||
| Q3 24 | $9.1B | $12.8B | ||
| Q2 24 | $9.0B | $13.4B | ||
| Q1 24 | $9.0B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $218.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $214.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 28.8% | 21.0% |
| 资本支出强度资本支出/营收 | 0.5% | 2.6% |
| 现金转化率经营现金流/净利润 | 5.07× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $904.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流OKTARVTY
| Q4 25 | $218.0M | $182.0M | ||
| Q3 25 | $167.0M | $138.5M | ||
| Q2 25 | $241.0M | $134.3M | ||
| Q1 25 | $286.0M | $128.2M | ||
| Q4 24 | $159.0M | $174.2M | ||
| Q3 24 | $86.0M | $147.9M | ||
| Q2 24 | $219.0M | $158.6M | ||
| Q1 24 | $174.0M | $147.6M |
自由现金流OKTARVTY
| Q4 25 | $214.0M | $161.8M | ||
| Q3 25 | $165.0M | $120.0M | ||
| Q2 25 | $240.0M | $115.5M | ||
| Q1 25 | $285.0M | $112.2M | ||
| Q4 24 | $158.0M | $149.8M | ||
| Q3 24 | $81.0M | $125.6M | ||
| Q2 24 | $218.0M | $136.6M | ||
| Q1 24 | $171.0M | $129.7M |
自由现金流率OKTARVTY
| Q4 25 | 28.8% | 21.0% | ||
| Q3 25 | 22.7% | 17.2% | ||
| Q2 25 | 34.9% | 16.0% | ||
| Q1 25 | 41.8% | 16.9% | ||
| Q4 24 | 23.8% | 20.5% | ||
| Q3 24 | 12.5% | 18.4% | ||
| Q2 24 | 35.3% | 19.7% | ||
| Q1 24 | 28.3% | 20.0% |
资本支出强度OKTARVTY
| Q4 25 | 0.5% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.1% | 2.4% | ||
| Q4 24 | 0.2% | 3.4% | ||
| Q3 24 | 0.8% | 3.3% | ||
| Q2 24 | 0.2% | 3.2% | ||
| Q1 24 | 0.5% | 2.7% |
现金转化率OKTARVTY
| Q4 25 | 5.07× | 1.85× | ||
| Q3 25 | 2.49× | 2.97× | ||
| Q2 25 | 3.89× | 2.49× | ||
| Q1 25 | 12.43× | 3.03× | ||
| Q4 24 | 9.94× | 1.84× | ||
| Q3 24 | 2.97× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OKTA
| Subscription And Circulation | $724.0M | 98% |
| Technology Service | $18.0M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
